These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 20434256)

  • 1. The predictive value of pre-treatment cystometry in the outcome of women with mixed incontinence treated with duloxetine.
    Vella M; Duckett J; Basu M
    Eur J Obstet Gynecol Reprod Biol; 2010 Aug; 151(2):221-3. PubMed ID: 20434256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tolerability and efficacy of duloxetine in a nontrial situation.
    Duckett JR; Vella M; Kavalakuntla G; Basu M
    BJOG; 2007 May; 114(5):543-7. PubMed ID: 17355360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Duloxetine compared with placebo for treating women with symptoms of overactive bladder.
    Steers WD; Herschorn S; Kreder KJ; Moore K; Strohbehn K; Yalcin I; Bump RC;
    BJU Int; 2007 Aug; 100(2):337-45. PubMed ID: 17511767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mixed urinary incontinence symptoms: urodynamic findings, incontinence severity, and treatment response.
    Bump RC; Norton PA; Zinner NR; Yalcin I;
    Obstet Gynecol; 2003 Jul; 102(1):76-83. PubMed ID: 12850610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Recommendations for the urodynamic examination in the investigation of non-neurological female urinary incontinence].
    Hermieu JF;
    Prog Urol; 2007 Nov; 17(6 Suppl 2):1264-84. PubMed ID: 18214138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Duloxetine versus placebo in the treatment of European and Canadian women with stress urinary incontinence.
    van Kerrebroeck P; Abrams P; Lange R; Slack M; Wyndaele JJ; Yalcin I; Bump RC;
    BJOG; 2004 Mar; 111(3):249-57. PubMed ID: 14961887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Duloxetine versus placebo in the treatment of stress urinary incontinence.
    Norton PA; Zinner NR; Yalcin I; Bump RC;
    Am J Obstet Gynecol; 2002 Jul; 187(1):40-8. PubMed ID: 12114886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of duloxetine on quality of life for women with symptoms of urinary incontinence.
    Kinchen KS; Obenchain R; Swindle R
    Int Urogynecol J Pelvic Floor Dysfunct; 2005; 16(5):337-44. PubMed ID: 15662490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pre-operative opening detrusor pressure is predictive of detrusor overactivity following TVT in patients with pre-operative mixed urinary incontinence.
    Panayi DC; Duckett J; Digesu GA; Camarata M; Basu M; Khullar V
    Neurourol Urodyn; 2009; 28(1):82-5. PubMed ID: 19089898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is pretreatment cystometry important in predicting response to mirabegron in women with overactive bladder symptoms?
    Basu M; Balachandran A; Duckett J
    Int Urogynecol J; 2016 Mar; 27(3):427-31. PubMed ID: 26282091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Duloxetine compared with placebo for the treatment of women with mixed urinary incontinence.
    Bent AE; Gousse AE; Hendrix SL; Klutke CG; Monga AK; Yuen CK; Muram D; Yalcin I; Bump RC
    Neurourol Urodyn; 2008; 27(3):212-21. PubMed ID: 17580357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of duloxetine in elderly women with stress urinary incontinence or stress-predominant mixed urinary incontinence.
    Schagen van Leeuwen JH; Lange RR; Jonasson AF; Chen WJ; Viktrup L
    Maturitas; 2008 Jun; 60(2):138-47. PubMed ID: 18547757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Duloxetine for mild to moderate postprostatectomy incontinence: preliminary results of a randomised, placebo-controlled trial.
    Cornu JN; Merlet B; Ciofu C; Mouly S; Peyrat L; Sèbe P; Yiou R; Vallancien G; Debrix I; Laribi K; Cussenot O; Haab F
    Eur Urol; 2011 Jan; 59(1):148-54. PubMed ID: 21030144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on duloxetine for the management of stress urinary incontinence.
    Basu M; Duckett JR
    Clin Interv Aging; 2009; 4():25-30. PubMed ID: 19503763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short- and long-term efficacy and safety of duloxetine in women with predominant stress urinary incontinence.
    Cardozo L; Lange R; Voss S; Beardsworth A; Manning M; Viktrup L; Zhao YD
    Curr Med Res Opin; 2010 Feb; 26(2):253-61. PubMed ID: 19929591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological treatment of women awaiting surgery for stress urinary incontinence.
    Cardozo L; Drutz HP; Baygani SK; Bump RC
    Obstet Gynecol; 2004 Sep; 104(3):511-9. PubMed ID: 15339761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Duloxetine versus placebo for the treatment of North American women with stress urinary incontinence.
    Dmochowski RR; Miklos JR; Norton PA; Zinner NR; Yalcin I; Bump RC;
    J Urol; 2003 Oct; 170(4 Pt 1):1259-63. PubMed ID: 14501737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The predictive value of preoperative pressure-flow studies in the resolution of detrusor overactivity and overactive bladder after tension-free vaginal tape insertion.
    Duckett JR; Basu M
    BJU Int; 2007 Jun; 99(6):1439-42. PubMed ID: 17419703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of duloxetine on urethral function and sphincter morphology.
    Athanasiou S; Chaliha C; Digesu GA; Sotiropoulou M; Georgoulias N; Khullar V; Antsaklis A
    Int Urogynecol J Pelvic Floor Dysfunct; 2007 Jul; 18(7):763-7. PubMed ID: 17061027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short-term test-retest reproducibility of urethral pressure profilometry in women with urodynamic stress incontinence with and without detrusor overactivity.
    Rahmanou P; Khullar V
    Neurourol Urodyn; 2011 Sep; 30(7):1356-60. PubMed ID: 21538497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.